Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes

BACKGROUND. Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients....

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Clin Invest
Hoofdauteurs: Ramos, Carlos A., Ballard, Brandon, Zhang, Huimin, Dakhova, Olga, Gee, Adrian P., Mei, Zhuyong, Bilgi, Mrinalini, Wu, Meng-Fen, Liu, Hao, Grilley, Bambi, Bollard, Catherine M., Chang, Bill H., Rooney, Cliona M., Brenner, Malcolm K., Heslop, Helen E., Dotti, Gianpietro, Savoldo, Barbara
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society for Clinical Investigation 2017
Onderwerpen:
Clinical Medicine
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5669573/
https://ncbi.nlm.nih.gov/pubmed/28805662
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI94306
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items